Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Federal Trade Commission
US Department of Justice
Moodys
Covington
Daiichi Sankyo
Cipla
McKinsey
Merck

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,101,543

« Back to Dashboard

Which drugs does patent 9,101,543 protect, and when does it expire?


Patent 9,101,543 protects ABRAXANE and is included in one NDA. There has been one Paragraph IV challenge on Abraxane.

This patent has seventy-three patent family members in twenty-five countries.

Summary for Patent: 9,101,543

Title:Combinations and modes of administration of therapeutic agents and combination therapy
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: ABRAXIS BIOSCIENCE, LLC (Los Angeles, CA)
Application Number:13/585,696
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Abraxis BioscienceABRAXANEpaclitaxelFOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF PANCREATIC CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,101,543

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,561,288Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
7,758,891Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,735,394Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,257,733Methods and compositions for treating proliferative diseases► Subscribe
8,268,348Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,034,375Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
7,780,984Methods and compositions for treating proliferative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,101,543

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel244390► Subscribe
China101573108► Subscribe
China103169729► Subscribe
China103285395► Subscribe
China104940929► Subscribe
China105288630► Subscribe
Cyprus1112907► Subscribe
Cyprus1115271► Subscribe
Cyprus1117725► Subscribe
Denmark1853250► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Fuji
Teva
Colorcon
Johnson and Johnson
Covington
UBS
Boehringer Ingelheim
Federal Trade Commission
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot